Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Synthetic peptide composition to inhibit inflammatory activity to aid in drug and biomaterial delivery

Description:

Anti-SIRP peptide binds to phagocytes to circumvent immune response to foreign materials 

 

Inventor

Dennis Discher , Professor, Chemical and Biomolecular Engineering 

 

Problem

The immune system efficiently recognizes foreign materials upon introduction to the body.  Phagocytes are immune cells that protect the body by ingesting foreign particles, bacteria, and dying cells.  Phagocytes also plan a role in inflammatory diseases, such as arthritis.  While the phagocytic response is typically beneficial for clearing pathogens, it is a limitation when clinical treatment relies on a biomaterial implant or drug delivery vehicle, such as stents and nanoparticles.  The body’s response to the foreign entity results in premature clearance of the material or an immune reaction that hinders the efficacy of the treatment regimen.

 

Solution

Researchers in the Discher lab have developed a small synthetic peptide based on CD47 that can be attached to or coadministered with viruses, nanoparticles, or biomaterials to mask the foreign matter, allowing for more effective therapeutics.  The peptide acts as a “self” signal to effectively reduce the body’s natural response to engulf the material; it binds to the SIRP-α signal on phagocytes to prevent phagocytes from eating “self” entities.  The lab has demonstrated that nanobeads circulate longer in the bloodstream when coated with the “self” peptide. 

 

 

 

Advantages

•       Increase circulation of drug in blood

•       Minimize inflammatory response to foreign objects

•       Reduce platelet activation and clotting on blood-contacting materials

 

Applications

•       Drug delivery

•       Coat any non-tissue material entering body

•       Inflammatory diseases/arthritis treatment

•       Autoimmune diseases

 

 

Stage of Development

In vitro and in vivo testing 

 

Intellectual Property

UP application (US 20140140926 A1)

 

Reference Media

NIH Highlight

Penn News highlight 1

Penn News highlight 2

Rodriguez PL, et al.  Science, 2013, 339(6122): 971-975.

Tsai RK, et al.  Journal of Cell Biology, 2008, 180: 989-1003 .  Cover Article.

 

 

Desired partnerships

•  License

Co-development

 

 

Download PDF

 

Docket #   X5663


Patent Information:
For Information, Contact:
Joshua Jeanson
Associate Director, SEAS/SAS Licensing Group
University of Pennsylvania
jeanson@upenn.edu
Inventors:
Dennis Discher
Keywords: